Metformin attenuates diabetic renal injury via the AMPK-autophagy axis

TINGLI SUN¹, JIZHANG LIU¹, CHANGYING XIE¹, JUN YANG¹, LIJIE ZHAO² and JINGBO YANG¹

Departments of ¹Nephrology and ²Geriatrics, General Hospital of Daqing Oil Field, Daqing, Heilongjiang 163001, P.R. China

Received March 27, 2019; Accepted November 19, 2020

DOI: 10.3892/etm.2021.10010

Abstract. Diabetic nephropathy (DN) is a clinical condition characterized by kidney damage that is observed in patients with diabetes. DN is the main cause of end-stage renal disease (ESRD), which is the final stage of chronic kidney disease. Increasing evidence suggests that metformin, a characteristic oral hypoglycemic drug used for treating diabetes, exerts beneficial effects on various medical conditions and diseases, including cancer, cardiovascular diseases and thyroid-related disorders. However, the impact of metformin on DN remains unknown. The present study investigated whether metformin could attenuate the inflammatory response, fibrosis and increased oxidative stress observed during DN in diabetic/dyslipidemic (db/db) mice. The kidneys of the mice (12-16 weeks) were isolated for immunohistochemistry and western blotting. The results demonstrated that metformin significantly reduced the oxidative damage and fibrosis in the kidneys of db/db mice. Furthermore, metformin treatment significantly inhibited the generation of inflammatory cytokines, including TNF-α and IL-1β in db/db mice. These effects were induced by the activation of the AMP-activated protein kinase (AMPK) pathway, which was mediated by increased phosphorylation of AMPK and mammalian target of rapamycin (mTOR), resulting in autophagy and the simultaneous decrease in reactive oxygen species production, cell apoptosis and inflammatory response. These findings suggested that metformin may reduce DN damage via regulation of the AMPK-mTOR-autophagy axis and indicated that metformin may be considered as a potential target in the treatment of DN.

Introduction

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide (1). The development of DN is associated with hypertension, elevated urinary albumin levels, glomerulosclerosis and a decline in the glomerular filtration rate, ultimately resulting in ESRD (2). These alterations are associated with remodeling of the kidney structure, including glomerular and tubular hypertrophy, extracellular matrix (ECM) aggregation and inflammatory responses (3). Even in patients with diabetes who are able to maintain normal blood glucose levels and blood pressure, a progressive decline in kidney function and a gradual development of renal injury are observed (4). The development of innovative approaches to delay DN progression is therefore of great clinical importance.

A previous study reported that chronic aseptic inflammatory responses may have a crucial impact on the development and progression of DN (5). Furthermore, it was recently demonstrated that diabetic kidney fibrosis is responsible for chronic inflammatory responses (6,7). DN is therefore considered to induce a renal inflammatory response, which is characterized by inflammatory cell infiltration and inflammatory cytokine upregulation (8-10). For example, T cells and macrophages have been demonstrated to accumulate in the kidney interstitium and glomeruli in human DN, even at the initial stage of the disease. Furthermore, hyperglycemia and glycated hemoglobin, which are hallmarks of diabetes, have been indicated to be associated with renal inflammatory responses (10). As demonstrated in diabetic models, enhanced production of chemokines and cytokines aggravate the inflammatory response (11,12). Subsequently, inhibition of renal inflammatory cell accumulation has been demonstrated to be protective in experimental DN (13). Another factor contributing to the progression of DN is the increased generation of reactive oxygen species (ROS). Recent studies have reported that a high-glucose environment triggered increased ROS production, which caused major pathophysiological alterations in DN via increased ECM accumulation and cell death (14,15). Pharmacological or genetic blockages of inflammatory responses and ROS production may therefore represent promising approaches to treat DN.

Metformin is a biguanide agent that is commonly used to treat type 2 diabetes (16). Metformin reinforces hepatic and peripheral tissue sensitivity to insulin and reduces the amount of sugar produced by the liver and released in the bloodstream (16,17). Metformin is an antihyperglycemic agent that is associated with low risk of hypoglycemia compared with other anti-diabetic drugs such as sulfonylurea hypoglycemic agents. Considering its favorable effects on serum lipid
levels, obese body condition, cardiovascular disease and mortality, metformin is recommended as the first-line pharmacotherapy for patients with type 2 diabetes. The US Food and Drug Administration recommends, therefore, that metformin hydrochloride should be taken for 6 months from the beginning of DN (17). Metformin has also been reported to be an activator of AMP-activated protein kinase (AMPK) via the increased phosphorylation of AMPK at Thr172, which in turn induces mitophagy and macroautophagy, which protects against DN (18). Metformin has been used to treat various diseases, including diabetes (19), cardiovascular diseases (20), cancer (21), Alzheimer’s disease (22) and Huntington’s disease (23). However, the effect of metformin on DN remains to be completely elucidated. The present study investigated the effects of metformin on DN and its potential underlying mechanisms using diabetic/dyslipidemic (db/db) mice as a model of type 2 diabetes.

Materials and methods

Animals. Wild-type (WT; 12-16 weeks; male; n=16) and transgenic db/db mice (n=32; 12-16 weeks; male) were purchased from the Jackson Laboratory. WT littermates served as the control group. Mice were kept in the animal facility of the General Hospital of Daqing Oil Field at 22°C with a 12-h light/dark cycle and 50-60% humidity. Animals had free access to food and water. All mice were intraperitoneally injected with metformin (Sigma-Aldrich; Merck KGaA; 200 mg/kg/day) for 7 days. The mice were divided into three groups as follows: WT (n=16); db/db (n=16); and db/db + metformin (n=16). The body weights of the mice were measured every 3 days. The toxicity of metformin was assessed by monitoring the general condition of the mice, such as the lifespan. Subsequently, the mice were sacrificed, and their kidneys were quickly excised, weighed and immediately frozen at -80°C prior to further experiments. All experiments were approved by the Animal Ethics Committee of the General Hospital of Daqing Oil Field (Daqing, China).

Tissue histology and immunohistochemistry (IHC). Kidney specimens were fixed overnight in 4% paraformaldehyde at 20°C, embedded into paraffin and cut into 4-µm thick sections. IHC staining was performed on these sections using the Histostain-SP IHC kit (Beyotime Institute of Biotechnology) according to the manufacturer’s instructions. Briefly, paraffin-embedded tissue sections were deparaffinized with xylene and rehydrated using graded ethanol (30%, 0.5 h; 50%, 0.5 h; 70%, 0.5 h; 80%, 0.5 h; 95%, 0.5 h and 100%, 1 h). The sections were then treated with 3% hydrogen peroxide prepared in 100% ethanol for 1 h at 20°C to deactivate the cellular peroxidases. For antigen retrieval, specimens were immersed in sodium citrate buffer (pH 6.0) and autoclaved at 121°C for 15 min. The sections were then blocked in 10% goat serum (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature and incubated overnight with primary antibody against fibronectin (cat. no. 26836; 1:1,000; Cell Signaling Technology, Inc.) at 4°C. After washing with 0.1% TBS-Tween-20 (TBS-T) to remove the unbound antibody, the sections were incubated with biotinylated secondary antibody (cat. no. 7074; 1:5,000; Cell Signaling Technology, Beverly, Inc.) detected using streptavidin-conjugated HRP. The slides were subsequently stained with 3,3′-diaminobenzidine for 10 min at 20°C, resulting in the formation of a brown product, whereas hematoxylin was used as the counterstain for 10 min at 20°C. Deparaffinized sections were also stained with Masson’s trichrome stain and visualized under light microscopy (×20 magnification) independently by blinded investigators. The tubular interstitial damage score was graded on a scale from 0 to 4 in each of the assessed glomeruli. Scores of 0, 1, 2, 3 and 4 were assigned to normal glomeruli, 1-25%, 26-50%, 51-75% and >75% of staining intensity, respectively. Quantitative analysis was performed using six random fields analyzed in a blinded manner with the Image-Pro Plus version 6.0 software (Media Cybernetics, Inc.).

Reverse transcription-quantitative PCR (RT-qPCR). TRIZol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from kidney tissues. RT was performed using a PrimeScript RT reagent kit (Takara Bio, Inc.) according to the manufacturer's instructions. qPCR was performed using a QuantStudio SYBR Green PCR kit (Qiagen GmbH) on an ABI 7300 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR thermocycling conditions were as follows: Initial denaturation for 5 min at 95°C; followed by 36 cycles of 10 sec at 95°C, 10 sec at 58°C and 20 sec at 72°C. GAPDH was used as an internal control for qPCR amplification. The relative quantification of target gene was conducted by using the 2^ΔΔCq method (24). The following primer pairs were used for the qPCR: GAPDH forward, 5′-CAAAGGGTCTACTTCC-3′ and reverse, 5′-CCCCAGACTCAAAAGGTGT-3′; TGF-β forward, 5′-TCATTGTGGCCTGTGAGAG-3′ and reverse, 5′-AGGCCACAGGTTTTTGCG-3′ and TNF-α forward, 5′-CATCTTCTCAAAAATTCCGA-3′ and reverse, 5′-TGGAAGTAGACAGGTACCACCC-3′.

TUNEL assay. TUNEL assay was performed using a TUNEL staining kit (Roche Diagnostics) to evaluate DNA fragmentation and detect renal cell apoptosis, according to the manufacturer's instructions. Renal slices were embedded into paraffin and sliced into 4-µm sections. The sections were deparaffinized and rehydrated as aforementioned, and subsequently treated with proteinase K and TUNEL reaction mixture for 1 h at 37°C. The nuclei were subsequently stained with DAPI for 10 min at 20°C. For each specimen, five random fields (without overlaps) were counted to determine the cells with TUNEL-positive signal (magnification, ×400) under a light microscope.

ROS assessment in kidneys. Kidney specimens were fixed overnight in 4% paraformaldehyde at 20°C, embedded into paraffin and cut into 4-µm thick sections. The formation of ROS in the kidneys was determined using dihydroethidium (DHE; 1:1,000; MilliporeSigma) staining for 30 min at 37°C on renal 5-µm sections. The nucleus was subsequently stained with DAPI for 10 min at 20°C. Images were captured using the Nikon Eclipse Ti-U fluorescence microscope (Nikon Corporation) supplemented with a high-resolution digital camera (magnification, ×400). The mean fluorescence intensity of at least six random fields analyzed in a blinded manner was...
calculated using Image-Pro Plus version 6.0 software (Media Cybernetics, Inc.).

Western blotting. Tissue samples (20 mg) were lysed with RIPA lysis buffer (Beyotime Institute of Biotechnology). Protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Inc.). The proteins (20 µg) were separated using 8-15% gradient SDS-PAGE (Bio-Rad Laboratories, Inc.) and transferred onto PVDF membranes (EMD Millipore). The membranes were blocked with 10% FBS (Sigma-Aldrich; Merck KGaA) for 1 h at 20˚C and incubated overnight at 4˚C with primary antibodies against Beclin 1 (cat. no. 3495; 1:1,000), microtubule-associated proteins 1A/1B light chain 3 (LC3) (cat. no. 3868; 1:1,000), AMPK (cat. no. 5831; 1:1,000), mTOR (cat. no. 4517; 1:1,000), p70S6 kinase (p70S6K; cat. no. 2708; 1:1,000), IL-1β (cat. no. 12703; 1:1,000), fibronectin (cat. no. 26836; 1:1,000), p62 (cat. no. 23214; 1:1,000), phosphorylated (p)-AMPK (cat. no. 50081; 1:1,000), p-mTOR (cat. no. 2971; 1:1,000), p-p70S6K (cat. no. 9209; 1:1,000), TNF-α (cat. no. 11948; 1:1,000), p-p65 (cat. no. 3033; 1:1,000), Bax (cat. no. 5023; 1:1,000), Bcl2 (cat. no. 3498; 1:1,000) and β-actin (cat. no. 4970; 1:1,000) dissolved in 0.1% TBS-T Tween-20. All primary antibodies were purchased from Cell Signaling Technology, Inc. The membranes were washed with 0.1% TBS-T to remove unbound antibodies and incubated with HRP-conjugated secondary antibody (Caltag Lab, Inc.) and analyzed with ImageQuant™ LAS 4000 imaging system (GE Healthcare Bio-Sciences). Protein levels were determined by normalizing to the levels of β-actin.

Statistical analysis. Data are presented as the mean ± SEM or the median and interquartile range. Data were analyzed using GraphPad Prism 7 (GraphPad Software, Inc.). Differences among various groups were analyzed using one-way ANOVA followed by Tukey’s post hoc test or Kruskal-Wallis followed by Dunn’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Metformin prevents fibrosis in diabetic kidneys. Renal fibrosis, which is characterized by excessive generation and deposition of ECM and fibroblast activation, is one of the key features in the development of DN (25). The present study explored whether metformin attenuated diabetic renal damage, and whether this was mediated by the repression of renal fibrosis. The results demonstrated that metformin treatment did not affect db/db mouse body weight (Fig. 1A). Furthermore, diabetic mice were presented with hallmarks of DN, including increased accumulation of mesangial matrix, glomerular and tubular vacuolar degradation and interstitial fibrosis. However, these alterations were significantly reduced in db/db mice treated with metformin (Fig. 1B and C). In addition, fibronectin protein expression was significantly upregulated in db/db mice compared with WT mice, whereas metformin treatment significantly downregulated fibronectin expression in the diabetic kidneys (Fig. 1D and E). These findings suggested that metformin treatment may attenuate renal fibrosis in the DN mouse model, in particular in the glomerulus.

Metformin prevents ROS-mediated cell apoptosis in diabetic kidneys. DN is associated with ROS overproduction (15). The impact of metformin on ROS generation was therefore assessed in the diabetic mice. The results demonstrated that metformin treatment significantly downregulated fibronectin expression in the diabetic kidneys (Fig. 1D and E). These findings suggested that metformin treatment may attenuate renal fibrosis in the DN mouse model, in particular in the glomerulus.
significantly increased Bcl2 expression and reduced Bax expression in db/db mice (Fig. 2E-G). These results indicated that metformin may inhibit ROS-mediated cell apoptosis in the kidneys of mice with DN.

**Metformin impairs inflammatory responses in DN.** The expression of proinflammatory cytokines, including IL-1β and TNF-α, in diabetic mice was assessed to verify whether metformin could influence inflammation in the kidneys. The results demonstrated that both IL-1β and TNF-α were significantly upregulated in diabetic mice compared with the control group; however, mice treated with metformin exhibited a significant reduction in IL-1β and TNF-α levels (Fig. 3), suggesting that metformin may attenuate the inflammatory response observed in diabetic mice. In addition, elevated expression of phosphorylated NF-κB p65 in diabetic mice was observed, which was significantly reduced following metformin treatment. These findings indicated that metformin may repress inflammatory responses in db/db mouse kidneys by preventing the induction of NF-κB, IL-1β and TNF-α.

**Metformin attenuates the defective autophagy in diabetic mice.** Autophagy serves as an adaptive cellular response to environmental stress, and its dysregulation has been associated with the development and progression of kidney diseases (26).

To elucidate the role of autophagy in DN, the expression of various proteins involved in autophagy was examined. The results demonstrated that LC3 and Beclin-1 protein expression level was significantly downregulated in db/db mice, whereas the expression level of p62, which is a marker of defective autophagy (18), was significantly increased in db/db compared with control mice (Fig. 4A-D). Furthermore, the expression level of these markers was significantly reversed following treatment with metformin, suggesting that metformin may attenuate the defective autophagy in DN.

**Metformin stimulates the AMPK-mTOR axis in DN.** The AMPK-mTOR axis is known to regulate autophagy; maintaining the cellular homeostasis via AMPK is considered to activate autophagy, whereas autophagy is inhibited by mTOR (27). The present study investigated whether metformin influenced autophagy via the AMPK-mTOR axis in diabetic mice. The results demonstrated that db/db mice exhibited increased mTOR and reduced AMPK activation in the kidneys compared with control mice, as evidenced by the enhanced phosphorylation of p70S6K (18) and mTOR and the decreased AMPK phosphorylation. However, metformin reversed these effects (Fig. 5A-D), suggesting that it may trigger autophagy via stimulation of the AMPK signaling pathway in the kidneys of db/db mice.
Discussion

Diabetic nephropathy is a chronic kidney disease caused by diabetes-related complications, including proteinuria and glomerulosclerosis. It is known to affect ~30% of patients with type 1 diabetes and ~10% of patients with type 2 diabetes (1). Numerous studies have reported the use of metformin in the treatment of various medical conditions in humans such as diabetes (22,23). However, its underlying mechanisms in DN or chronic kidney disease remain unknown. In the present study, diabetic mice exhibited hallmarks of DN, including accumulation of mesangial matrix, thickening of the glomerular basement membrane, hypertrophy of the glomerulus and effacement of podocytes. The present study demonstrated that metformin prevented these alterations in diabetic mice. This was observed by the reduced levels of fibronectin in kidneys following metformin treatment in db/db mice. Furthermore, various inflammatory cytokines triggered by diabetes, including IL-1β and TNF-α, were downregulated in diabetic mice following metformin treatment. Metformin also inhibited the expression of NF-κB. In addition, metformin inhibited ROS-induced apoptosis in the kidneys of diabetic mice since metformin reduced TUNEL staining and Bax expression. These findings suggested that metformin may present the potential to inhibit the development and progression of DN.

One of the common manifestations of DN includes the generation of an inflammatory response, which in turn aggravates the progression of DN (28). Uncontrolled diabetes may induce an inflammatory response that is characterized by infiltration of macrophages in the kidneys, causing ECM accumulation, fibrosis and renal malfunction, resulting in proteinuria and ESRD (28-30). Therefore, it is believed that the development of approaches that can reduce inflammation may be beneficial in the treatment of DN. Chronic inflammatory responses have been associated with the progression of DN, as demonstrated by the tubular damage and renal fibrosis caused by the infiltration of inflammatory cytokines, including IL-6, TNF-α and IL-1β, and the inducible nitric oxide synthase enzyme (29). Furthermore, it has been demonstrated that the inflammatory response is enhanced by the activation of the NF-κB signaling pathway that further stimulates the generation of proinflammatory cytokines and chemokines.
in mesangial cells (30). These molecules can subsequently drive tubular epithelial cells and podocytes to produce more cytokines and chemokines, resulting in interstitial immune cell infiltration, fibrosis and tubular damage (31,32). The present
study demonstrated that diabetes increased the expression of TNF-α, IL-1β and NF-κB in the kidneys, which was repressed following metformin treatment. Taken together, these findings indicated that metformin may impair the diabetes-mediated inflammatory response, thereby inhibiting the development of diabetes-mediated DN.

Although previous studies have explored the effect of autophagy on kidney function (33,34), its impact on DN remains unclear. Autophagy is a complex phenomenon that has been demonstrated to be involved in maintaining cellular homeostasis (35), but has also been associated with various diseases, including diabetes and hypertension (36). The findings of the present study revealed that autophagy was impaired in db/db mice compared with control mice. These results were in accordance with results from a previous study (37). Furthermore, the current study demonstrated that the defective autophagy was attenuated following metformin treatment. Autophagy is known to be regulated by nutrient-sensing mechanisms, including the AMPK-mTOR pathway (38). A previous study has reported that AMPK and mTORC1 function were inhibited and enhanced, respectively, in diabetic patients and animal models of type 1 and 2 diabetes with DN (38). The present study demonstrated that metformin exerted its effects by inducing AMPK activation and inhibiting mTOR function in db/db mice. These findings indicated that metformin may inhibit the kidney inflammatory response, ROS-mediated cell apoptosis and fibrosis via activation of the AMPK-autophagy axis. However, the present study did not distinguish the cell types where ROS were overproduced. A subsequent study will investigate which cell types are positive for DHE using cell-specific markers. In addition, the present study did not investigate whether metformin hydrochloride could decrease the incidence of DN in diabetic patients.

In conclusion, the results of the present study demonstrated that metformin exhibited protective effects against DN via regulating the AMPK-autophagy axis, suggesting that metformin may be considered as a promising target to treat DN.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
TS and JiY designed the study. JuY and LZ analyzed and interpreted the data. JL, LZ and CX performed the experiments. TS drafted the manuscript. JiY critically revised the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
The present study was approved by the Animal Ethics Committee of the General Hospital of Daqing Oil Field (Daqing, China).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. da Silva EG, Borges Dos Anjos LR, Mendes de Lima R, Alves TB, Pedrino GR, Helena da Silva Cruz A, da Silva Santos R, Frederia-Oliveira AH and da Silva Reis AA: Clinical data and risk factors for diabetic nephropathy in Brazilian central population. Data Brief 21: 1315-1320, 2018.
2. Chai Z, Wu T, Dai A, Huynh P, Koentgen F, Krippner G, Ren S and Cooper ME: Targeting the CDA1/CDA1B1P Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy. Diabetes 68: 395-408, 2019.
3. Du N, Xu Z, Gao M, Liu P, Sun B and Cao X: Combination of Ginsenoside Rgl and Atragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy. Drug Des Devel Ther 12: 3517-3524, 2018.
4. Qiu DD, Liu J, Shi JS, An Y, Ge YC, Zhou ML and Jiang S: Renoprotection provided by dipetidyl peptide-4 inhibitors in combination with angiotensin receptor blockers in patients with type 2 diabetic nephropathy. Chin Med J (Engl) 131: 2658-2665, 2018.
5. Chen F, Zhu X, Sun Z and Ma Y: Astilbin inhibits high glucose-induced inflammation and extracellular matrix accumulation by suppressing the TLR4/MyD88/NF-κB pathway in rat glomerular mesangial cells. Front Pharmacol 9: 1187, 2018.
6. Rovira-Llopis S, Escribano-Lopez I, Diaz-Morales N, Iannantuoni F, Lopez-Domenec S, Andújar J, Jover A, Pallardo LM, Bañuls C, et al: Downregulation of mir-31 in diabetic nephropathy and its relationship with inflammation. Cell Physiol Biochem 50: 1005-1014, 2018.
7. Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S and Egido F: Targeting inflammation in diabetic nephropathy: A tale of hope. Expert Opin Investig Drugs 27: 917-930, 2018.
8. Li J, Dong R, Yu J, Yi S, Da J, Yu F and Zha Y: Inhibitor of IGF1 receptor alleviates the inflammation process in the diabetic kidney mouse model without activating SOCS2. Drug Des Devel Ther 12: 2887-2896, 2018.
9. Eriguchi M, Bernstein EA, Veiras LC, Khan Z, Cao DY, Fuchs S, McDonough AA, Tobli JE, Gonzalez-Villalobos RA, Bernstein KE, et al: The absence of the ACE N-domain decreases renal inflammation and facilitates sodium excretion during diabetic kidney disease. J Am Soc Nephrol 29: 2546-2561, 2018.
10. Li J, Li N, Yan S, Liu M, Sun B, Lu Y and Shao Y: Ursolic acid alleviates inflammation and against diabetes induced nephropathy through TLR4-mediated inflammatory pathway. Mol Med Rep 18: 4675-4681, 2018.
11. Guirley SB, Ghosh S, Johnson SA, Azushima K, Sakban RB, George SE, Maeda M, Meyer TW and Coffman TM: Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy. Diabetes 67: 2096-2106, 2018.
12. Olatunji OJ, Chen H and Zhou Y: Lycium chinense leaves extract ameliorates diabetic nephropathy by suppressing hyperglycemia mediated renal oxidative stress and inflammation. Biomed Pharmacother 102: 1145-1151, 2018.
13. Zhang X, Guo K, Feng X, Zhao X, Huang Z and Niu JJBB: FGF23<sup>−/−</sup> improves diabetic nephropathy by attenuating renal fibrosis and inflammation. BMC Biotechnol 18: 33, 2018.
14. Chen X and Fang M: Oxidative stress mediated mitochondrial damage plays roles in pathogenesis of diabetic nephropathy rat. Eur Rev Med Pharmacol Sci 22: 5248-5254, 2018.
15. Zhang B, Zhang X, Zhang C, Shen Q, Sun G and Sun X: Notoginsenoside R1 protects db/db mice against diabetic nephropathy via upregulation of Nrfl2-mediated HO-1 expression. Molecules 24: 24, 2019.

16. Liu CH, Hua N, Fu X, Pan YL, Li B and Li XD: Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats. BMC Cardiovasc Disord 18: 236, 2018.

17. Ashamalla M, Youssif I, Yacoub M, Jayaramaiah A, Gupta N, Ray J, Iqbal S, Miller R, Singh J and McFarlane SI: Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy. Glob J Obes Diabetes Metab Syndr 5: 008-14, 2018.

18. Liu Y, Hu X, Shan X, Chen K and Tang H: Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway. Cancer Cell Int 19: 13, 2019.

19. Donnan K and Segar L: SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846: 23-29, 2019.

20. Abdellatif M, Sedej S, Carmona-Gutierrez D, Madeo F and Kroemer G: Autophagy in Cardiovascular Aging. Circ Res 123: 803-824, 2018.

21. Li DD, Guo JF, Huang JJ, Wang LL, Deng R, Liu JN, Feng GK, Xiao DJ, Deng SZ, Zhang XS and Zhu XF: Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PLoS One 5: e12176, 2010.

22. DiTacchio KA, Heinemann SF and Dziewczapolski G: Metformin treatment alters memory function in a mouse model of Alzheimer's disease. J Alzheimers Dis 44: 43-48, 2015.

23. Arnoux J, Willam M, Griesche N, Krumeich J, Watarı H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, et al: Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease. eLife 7: 7, 2018.

24. Livak JK and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

25. Huang S, Xu Y, Ge X, Xu B, Peng W, Jiang X, Shen L and Xia L: Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. J Cell Physiol. 2018.

26. Kim H, Dusabimana T, Kim SR, Je J, Jeong K, Kang MC, Cho KM, Kim JH and Park SW: Supplementation of abelmoschus manihot ameliorates diabetic nephropathy and hepatic steatosis by activating autophagy in mice. Nutrients 10: 10, 2018.

27. Liu L, Yang L, Chang B, Zhang J, Guo Y and Yang X: The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway. Ren Fail 40: 492-497, 2018.

28. Hu ZB, Ma KL, Zhang Y, Wang GH, Liu L, Lu J, Chen PP, Lu CC and Liu BC: Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy. Acta Pharmacol Sin 39: 1022-1033, 2018.

29. Cebeci E, Cakan C, Gursu M, Uzun S, Karadag S, Koldas M, Calhan T, Helvaci SA and Ozturk S: The main determinants of serum resistin level in type 2 diabetic patients are renal function and inflammation not presence of microvascular complication, Obesity and Insulin Resistance. Exp Clin Endocrinol Diabetes 127: 189-194 2019.

30. Heidari A, Hamidi G, Soleimanani A, Aghadavod E and Asemi Z: Effects of coenzyme Q10 supplementation on gene expressions related to insulin, lipid, and inflammation pathways in patients with diabetic nephropathy. Iran J Kidney Dis 12: 14-21, 2018.

31. Aroune D, Libdiri F, Leboucher S, Maouche B, Marco S and El-Aoufi S: Changes in the NFκB and E-cadherin expression are associated to diabetic nephropathy inPsammomys obsi. Saudi J Biol Sci 24: 843-850, 2017.

32. Jain SK, Croad JL, Velusamy T, Rains JL and Bull R: Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFκBp50, Akt, and Glut-2 in livers of zucker diabetic fatty rats. Mol Nutr Food Res 54: 1371-1380, 2010.

33. Liu X, Zhang Y, Shi M, Wang Y, Zhang F, Yan R, Liu L, Xiao Y and Guo B: Notch1 regulates PTEN expression to exacerbate renal tubulointerstitial fibrosis in diabetic nephropathy by inhibiting autophagy via interactions with Hes1. Biochem Biophys Res Commun 497: 1110-1116, 2018.

34. Zhang Y, Zhao S, Wu D, Liu X, Shi M, Wang Y, Zhang F, Bing J, Xiao Y and Guo B: MicroRNA-22 promotes renal tubulointerstitial fibrosis by targeting PTEN and suppressing autophagy in diabetic nephropathy. J Diabetes Res 2018: 4728645, 2018.

35. Wang X, Gao L, Liu H, Song J, Wang J, Yin Y, Zhao J, Xu X, Li Z and Li L: Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli. Eur J Pharmocol 824: 170-178, 2018.

36. Feng Y, Chen S, Xu J, Zhou Q, Ye X, Ding D, Yao W and Lu Y: Dysregulation of IncRNAs GM5524 and GM15645 involved in high glucose induced podocyte apoptosis and autophagy in diabetic nephropathy. Mol Med Rep 18: 3657-3664, 2018.

37. Pontrelli P, Oranger A, Barozzino M, Divella C, Conserva F, Fiore MG, Rossi R, Papale M, Castellano G, Simone S, et al: Deregulation of autophagy under hyperglycemic conditions is dependent on increased lysine 63 ubiquitination: A candidate mechanism in the progression of diabetic nephropathy. J Mol Med (Berl) 96: 645‑659, 2018.

38. Aroune D, Libdiri F, Leboucher S, Maouche B, Marco S and El-Aoufi S: Changes in the NFκB and E-cadherin expression are associated to diabetic nephropathy inPsammomys obsi. Saudi J Biol Sci 24: 843-850, 2017.